

Attorney Docket No.: FREE.P-001-2
PATENT APPLICATION
July 8, 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Andrade
Serial No : tba
Confirmation :
Filed : Herewith
Title : Regulation of Human Pluripotential Cells By Bone Morphogenetic Protein
2 Antagonists

SUBMISSION OF INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants request that the references listed on Substitute Form PTO-1449, which is enclosed, be made of record in the Patent Office file relating to the above-captioned application. Copies of the references should be available in the parent case, Serial No. 09/670,198.

The Applicants believe there are no fees due with this submission. However, if the Commissioner deems fees are due, the Commissioner is authorized to debit any fees deemed due from Deposit Account Number 15-0610.


Respectfully submitted,
OPPEDAHL & LARSON LLP



Marina T. Larson, PhD , Reg. No. 32,038
P.O. Box 5068
Dillon, CO 80435-5068
970-468-6600

I hereby certify that this paper and the attachments named herein are being deposited with the U.S. Postal Service as Express Mail No. EV332912554US in an envelope addressed to Commissioner of Patents, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.

7/9/03
Date


Linda L. Orr

Application No: TBA
Filing Date: Herewith
First Named Inventor: Andrade
Group Art Unit: 1645
Examiner Name:
Attorney Docket No.: FREE.P-001-2

Page 1 of 3

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner's Initials	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS
------------------------	---

_____ Bielman, A., Ovit, C.E., and Schuler, H.R. (1993). Oct 4: more than just a POUerful marker of the mammalian germline? AFMIS 106, 114-126.

_____ Coucouvanis, E., and Martin, G.R. (1999) BMP signalling plays a role in visceral endoderm differentiation and cavitation in the early mouse embryo. Development 126, 535-546.

_____ Heath, J.K. (1987). Experimental analysis of teratocarcinoma cell multiplication and purification of embryonal carcinoma derived growth factor. In Teratocarcinomas and embryonic stem cells: a practical approach. E.J. Robertson, ed. (Oxford: IRL Press), pp. 183-206.

_____ Herszfeld, D., Andrade, J., and Pera, M.F. (1999) Regulation of human pluripotent stem cell differentiation by bone morphogenetic protein-2. Poster presented at Combio 99, Gold Coast, Australia, 26-30 September.

_____ Latza, U., Foss, H.D., Durkop, H., Eitelbach, F., Dieckmann, K.P., Loy, V., Unger, M., Pizzolo, G., and Stein, H. (1995). CD30 antigen in embryonal carcinoma and embryogenesis and release of the soluble molecule. Am. J. Pathol. 146, 463-471.

_____ Pera, M.F., Bennett, W., and Cerretti, D.P. (1997). Expression of CD30 and CD30 ligand in cultured cell lines from germ cell tumours. Laboratory Investigation 76, 497-504.

_____ Pera, M.F., Cooper, S., Mills, J., and Parrington, J.M. (1989). Isolation and characterization of a multipotent clone of human embryonal carcinoma-cells. Differentiation 42, 10-23.

_____ Pera, M.F., and Herszfeld, D., (1998). Differentiation of human pluripotent teratocarcinoma stem cells induced by bone morphogenetic protein-2. Reproduction, Fertility and Development 10, 551-555.

_____ Pera et al. International Journal of Cancer. 40, 334-343 (1987), Cultured Stem Cells from Human Testicular Teratomas: The Nature of Human Embryonal Carcinoma, and its Comparison with Two Types of Yolk-Sac Carcinoma.

_____ Roach, S., Cooper, S., Bennett, W., and Pera, M.F. (1993). Cultured cell lines from human germ cell tumours: windows into tumour growth and differentiation and early human development. European Urology 23, 82-88.

_____ Roach, S., Schmid, W., and Pera, M.F. (1994). Hepatocytic transcription factor expression in human embryonal carcinoma and yolk-sac carcinoma cell lines - expression of hnf-3-alpha in models of early endodermal cell-differentiation. Exp. Cell Res. 215, 189-198.

This Information Disclosure Citation List is being submitted as a substitute for Form PTO-1449. The Examiner is requested to place his or her initials on the lines adjacent to the citations to indicate that the reference has been considered. The Examiner is further requested to fill in his or her name and the date the information was considered in blocks at the bottom of this substitute for Form PTO 1449.

Examiner _____ **Date Considered** _____